CHMP turns down Lilly’s Emgality for cluster headacheAn EMA advisory panel has rejected expanding the use of Eli Lilly’s Emgality to include prevention of episodic Share XCHMP turns down Lilly’s Emgality for cluster headachehttps://pharmaphorum.com/news/chmp-turns-down-lillys-emgality-for-cluster-headache/
Blow to Novartis as NICE rejects migraine drug Aimovig againAfter NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with Share XBlow to Novartis as NICE rejects migraine drug Aimovig againhttps://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/
Breakthrough migraine prevention treatment approved in EuropeNovartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine Share XBreakthrough migraine prevention treatment approved in Europehttps://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/
Migraine prevention drug Aimovig poised for EU approvalThe first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. The Share XMigraine prevention drug Aimovig poised for EU approvalhttps://pharmaphorum.com/news/migraine-prevention-aimovig-eu-approval/
